Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Perfuse Therapeutics

    Client Virtual Booth

    PERFUSE THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Perfuse Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1700 Owens Street, Suite 540 San Francisco, CA 94158
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://perfusetherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/perfusetherapeutics/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Perfuse Announces Initiation of Enrollment to Phase 2A Clinical Trial of PER001
    Perfuse Announces Initiation of Enrollment to Phase 2A Clinical Trial of PER001

    https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-initiation-of-enrollment-to-the-phase-2a-clinical-trial-of-per001-intravitreal-implant-in-diabetic-retinopathy-301892514.html

    PR NEWSWIRE
    03 Aug 2023
    Share Share
    Perfuse Announces Initiation of Enrollment to Phase 1/2a Trial of PER-001
    Perfuse Announces Initiation of Enrollment to Phase 1/2a Trial of PER-001

    https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-initiation-of-enrollment-to-ph2a-portion-of-the-phase-12a-clinical-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma-301881971.html

    PR NEWSWIRE
    20 Jul 2023
    Share Share
    Perfuse Announces Clearance of IND Application for Phase 1/2a Trial of PER-001
    Perfuse Announces Clearance of IND Application for Phase 1/2a Trial of PER-001

    https://www.prnewswire.com/news-releases/perfuse-therapeutics-announces-fda-clearance-of-ind-application-for-phase-12a-clinical-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma-301790222.html

    PR NEWSWIRE
    04 Apr 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search